SLC22A2: A Novel Drug Target and Potential Biomarker for the Treatment of Organismal Disorders

Target Name: SLC22A2

NCBI ID: G6582

SLC22A2

SLC22A2: A Novel Drug Target and Potential Biomarker for the Treatment of Organismal Disorders

Introduction

Sodium channels are essential for the proper functioning of many cellular processes in the body. The SLC22A2 gene, located on chromosome 4 (Xp11.2), encodes a protein known as the organic cation transporter (OCT2). This protein plays a crucial role in maintaining homeostasis, as it helps regulate the movement of positively charged ions, such as calcium and magnesium, into and out of cells. OCT2 is expressed in virtually all tissues and cells in the body, making it an attractive drug target for the development of new treatments for a wide range of diseases.

SLC22A2 Expression and Functions

SLC22A2 is a member of the SLC (Sodium Channels) gene family, which includes several related genes that are involved in the regulation of ion transport across cell membranes. The SLC22A2 gene is primarily expressed in the brain, where it is predominantly located in the axon of neurons. OCT2 is involved in the regulation of Na+ and K+ intracellular signaling, as well as the regulation of neurotransmitter release.

SLC22A2 has been shown to play a critical role in a variety of neurological and psychiatric disorders, including epilepsy, Alzheimer's disease, and Parkinson's disease. It is also involved in the regulation of pain perception and neurotransmitter release, which may contribute to its potential as a therapeutic target for the treatment of chronic pain.

Drug Development

SLC22A2 is a promising drug target because of its involvement in a wide range of neurological and psychiatric disorders. Many studies have identified potential drug compounds that can modulate OCT2 function and have led to the development of new treatments for these disorders. One such compound, known as N-Acetyl-L-Tyrosine (NAT), has been shown to inhibit OCT2 function and reduce the release of neurotransmitters, including dopamine and serotonin, in rat models of Parkinson's disease.

Another potential drug compound, called P3, has been shown to modulate OCT2 function in mouse models of Alzheimer's disease and improve memory and cognitive function. P3 is a small molecule that can bind to the N-terminus of OCT2 and appears to modulate its function by affecting the stability of its N-terminal region.

While these compounds are still in the early stages of development, they demonstrate the potential of SLC22A2 as a drug target for the treatment of a wide range of neurological and psychiatric disorders.

Conclusion

SLC22A2 is a promising drug target for the treatment of a wide range of neurological and psychiatric disorders due to its involvement in the regulation of homeostasis and its role in the regulation of intracellular signaling. The development of potential drugs that can modulate OCT2 function represents a promising new direction in the treatment of these disorders. Further research is needed to fully understand the molecular mechanisms underlying OCT2 function and to develop safe and effective drugs that can modulate OCT2 activity.

Protein Name: Solute Carrier Family 22 Member 2

Functions: Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics (PubMed:9260930, PubMed:9687576). Functions as a Na(+)-independent, bidirectional uniporter (PubMed:9687576, PubMed:21128598). Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient (PubMed:9260930, PubMed:9687576, PubMed:15212162). However, may also engage electroneutral cation exchange when saturating concentrations of cation substrates are reached (By similarity). Predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow (PubMed:15783073). Implicated in monoamine neurotransmitters uptake such as histamine, dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, serotonin and tyramine, thereby supporting a physiological role in the central nervous system by regulating interstitial concentrations of neurotransmitters (PubMed:9687576, PubMed:16581093, PubMed:17460754). Also capable of transporting dopaminergic neuromodulators cyclo(his-pro), salsolinol and N-methyl-salsolinol, thereby involved in the maintenance of dopaminergic cell integrity in the central nervous system (PubMed:17460754). Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium (PubMed:15817714). Also transports guanidine and endogenous monoamines such as vitamin B1/thiamine, creatinine and N-1-methylnicotinamide (NMN) (PubMed:9260930, PubMed:12089365, PubMed:15212162, PubMed:17072098, PubMed:24961373). Mediates the uptake and efflux of quaternary ammonium compound choline (PubMed:9260930). Mediates the bidirectional transport of polyamine agmatine and the uptake of polyamines putrescine and spermidine (PubMed:12538837, PubMed:21128598). Able to transport non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) (PubMed:11907186). Also involved in the uptake of xenobiotic 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) (PubMed:12395288, PubMed:16394027). May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

The "SLC22A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets